Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion type Assertion NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_head.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion description "[MCF-7 human breast cancer cells were treated with inhibitors for PLA2 (quinacrine), lipoxygenases (LOX-5 and LOX-12; baicalein, REV-5091, nordihydroguaiaretic acid), cyclooxygenases (COX-1, COX-2, indomethacin), and AROM (formestane).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_provenance.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion evidence source_evidence_literature NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_provenance.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion SIO_000772 18087590 NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_provenance.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion wasDerivedFrom befree-20150227 NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_provenance.
- NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_assertion wasGeneratedBy ECO_0000203 NP795214.RA9DAF52Dspf9Am8C42ZiyKJ1LR40L-HUkORfDN5Hgz4w130_provenance.